Commercialization of TrueContour® Custom Diabetic Foot Orthoses

Information

  • Research Project
  • 9461507
  • ApplicationId
    9461507
  • Core Project Number
    SB1DK059074
  • Full Project Number
    5SB1DK059074-09
  • Serial Number
    059074
  • FOA Number
    PAR-16-027
  • Sub Project Id
  • Project Start Date
    6/15/2001 - 23 years ago
  • Project End Date
    3/31/2019 - 5 years ago
  • Program Officer Name
    JONES, TERESA L Z
  • Budget Start Date
    4/1/2018 - 6 years ago
  • Budget End Date
    3/31/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    09
  • Suffix
  • Award Notice Date
    4/5/2018 - 6 years ago
Organizations

Commercialization of TrueContour® Custom Diabetic Foot Orthoses

Project Summary DIApedia, LLC, funded by the National Institutes of Health SBIR program, has developed an advanced diabetic foot orthosis system. DIApedia?s TrueContour® custom diabetic foot orthoses (CDFO) are designed by combining the patient?s unique foot shape with customized offloading modifications of the orthosis surface that are based on the patient?s unique measured plantar pressure. TrueContour® CDFOs have been clinically tested in head-to-head studies against diabetic shoe inserts currently approved by Medicare as ?best practice? and have been shown to 1) operate differently by significantly reducing plantar pressure via precise placement of offloading orthosis modifications (Owings et al. 2008) and 2) provide significant therapeutic distinction in reducing ulceration by 3.4 fold in patients at elevated risk for development of a diabetic plantar ulcer (Ulbrecht et al. 2014). The proposed project will address the remaining key cost drivers in the commercial scale manufacturing and distribution of the TrueContour® CDFO. Specifically, improvements to the orthosis design process and development of lower cost foot pressure measurement hardware will enable DIApedia and its commercialization partner to introduce the TrueContour® CDFO product to the therapeutic footwear marketplace. For the first time, therapeutic footwear providers and their patients will have access to custom diabetic foot orthoses with demonstrated clinical efficacy in the prevention of foot ulcer recurrence. We will collaborate with our commercialization partner and other key vendors to execute our work plan which is focused on completion of the following late stage development activities: A) Create TrueContour® custom insole design functionality in a commercial CADCAM software application. B) Develop and test a low-cost, high resolution plantar pressure measurement system. C) Integrate TrueContour® CDFO with our commercial partner?s in-clinic patient data acquisition system.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    SB1
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    94991
  • Indirect Cost Amount
    37996
  • Total Cost
    142296
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:142296\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIAPEDIA, LLC
  • Organization Department
  • Organization DUNS
    115331691
  • Organization City
    STATE COLLEGE
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    168017097
  • Organization District
    UNITED STATES